Bionomics Limited
31 Dalgleish Street
Thebarton
South Australia
5031
Australia
Tel: 618-8354-6100
Fax: 618-8354-6199
Website: http://www.bionomics.com.au/
Email: info@bionomics.com.au
102 articles with Bionomics Limited
-
Bionomics Limited Release: Latest BNC210 Anxiety Drug Data to Be Presented at US Neuroscience Conference
11/15/2010
-
Bionomics Limited Announces $15 Million Capital Raising
9/8/2009
-
Bionomics Limited Start-Up Placement with Australian Ventures
9/3/2009
-
Bionomics Limited Extends Contract of CEO and Managing Director Deborah Rathjen
8/8/2008
-
Bionomics Limited Completes GMP Synthesis of Anti-Anxiety Drug BNC210
7/9/2008
-
Merck Serono and Bionomics Limited Announce Multiple Sclerosis Development and Licensing Agreement
6/18/2008
-
Bionomics Limited Advances BNC210, Anti-anxiety Lead Candidate
3/11/2008
-
Treatment of First Patient in Phase I Clinical Trial of Bionomics Limited's Anti-Cancer Drug BNC105
2/26/2008
-
Bionomics Limited Achieves US$1 Million Milestone Payment from Genmab A/S
2/19/2008
-
Bionomics Limited Anti-Cancer Compound Targets Tumour, Not Healthy Tissue
10/4/2007
-
Bionomics Limited' 2006/2007 Preliminary Final Results
8/30/2007
-
Backing for Bionomics Limited to Test Anti-Cancer Compound
8/6/2007
-
Bionomics Limited Presents Multiple Sclerosis and Anxiety Data
7/13/2007
-
Bionomics Limited Raises $10 Million in Private Placement
6/20/2007
-
Bionomics Limited' Validates Third Cancer Application For Anti-Cancer Compound BNC105
6/4/2007
-
Bionomics Limited Completes GMP Synthesis Of Cancer Drug Bnc105 On Time And On Budget
4/23/2007
-
Bionomics Limited Takes Key Step Forward in the Development of Anti-Cancer Drug Bnc105
2/21/2007
-
Bionomics Limited And SAFC Pharma Sign Contract To Manufacture BNC105
10/25/2006
-
Genmab A/S Licenses Angiogenesis Targets From Bionomics Limited
2/14/2006
-
Bionomics Limited Licenses Two Epilepsy Diagnostics To Laboratory Corporation of America Holdings
11/3/2005